Dr. Bernard Thébaud lives in two very different worlds. As a specialist in the Stollery Children's Hospital's Neonatal Intensive Care Unit at the Royal Alexandra Hospital, he cares for tiny babies, many of whom struggle for breath after being born weeks before they are due.
Across town, in his laboratory in the Faculty of Medicine & Dentistry at the University of Alberta, Dr. Thébaud dons a lab coat and peers into a microscope to examine the precise effect of stem cells on the lungs.
Today, with his scientific research being published in the American Journal of Respiratory and Critical Care Medicine, Dr. Thébaud has made a significant leap to bridge the gap between those two worlds.
An international team of scientists led by Dr. Thébaud has demonstrated for the first time that stem cells protect and repair the lungs of newborn rats. "The really exciting thing that we discovered was that stem cells are like little factories, pumping out healing factors," says Dr. Thébaud, an Alberta Heritage Foundation for Medical Research Clinical Scholar. "That healing liquid seems to boost the power of the healthy lung cells and helps them to repair the lungs."
In this study, Thébaud's team simulated the conditions of prematurity – giving the newborn rats oxygen. The scientists then took stem cells, derived from bone marrow, and injected them into the rats' airways. Two weeks later, the rats treated with stem cells were able to run twice as far, and had better survival rates. When Thébaud's team looked at the lungs, they found the stem cells had repaired the lungs, and prevented further damage.
"I want to congratulate Dr. Thébaud and his team. This research offers real hope for a new treatment for babies with chronic lung disease," says Dr. Roberta Ballard, professor of pediatrics, University of California, San Francisco. "In a few short years, I anticipate we will be able to take these findings and begin clinical trials with premature babies."
"The dilemma we face with these tiny babies is a serious one. When they are born too early, they simply cannot breathe on their own. To save the babies' lives, we put them on a ventilator and give them oxygen, leaving many of them with chronic lung disease," says Dr. Thébaud. "Before the next decade is out I want to put a stop to this devastating disease."
The research team includes physicians and scientists from Edmonton, Alberta, Tours, France, Chicago, Illinois, and Montreal, Quebec.
The team is now investigating the long-term safety of using stem cells as a lung therapy. The scientists are examining rats at 3 months, and 6 months after treatment, studying the lungs, and checking their organs to rule out any risk of cancer. Dr. Thébaud's team is also exploring whether human cord blood is a better option than bone marrow stem cells in treating lung disease.
"We are also studying closely the healing liquid produced by the stem cells," says Dr. Thébaud. "If that liquid can be used on its own to grow and repair the lungs, that might make the injection of stem cells unnecessary."
Dr. Thébaud is a neonatal specialist for Alberta Health Services, and a Canada Research Chair in Translational Lung and Vascular Development Biology. His research is supported by the AHFMR, the Canada Foundation for Innovation, the Canadian Institutes of Health Research, the Canadian Stem Cell Network and the Stollery Children's Hospital Foundation.
The study, Airway Delivery of Mesenchymal Stem Cells prevents Arrested Alveolar Growth In Neonatal Lung Injury In Rats, is available at http://ajrccm.atsjournals.org/current.shtml
Still photos and video content (including a premature baby and her parents) are available for download at www.ahfmr.ab.ca
Media please contact Karen Thomas, AHFMR Media Specialist, 1.877.423.5727 x 225, 1.403.651.1112 (cell), Karen.email@example.com
For more information on this research contact Dr. Bernard Thébaud at firstname.lastname@example.org
Alberta has the highest rate of premature births in Canada with a rate of 9.2% compared to the rest of Canada at 7.8%.
Babies who are born extremely premature – before 28 weeks – cannot breathe on their own. In order to help the babies' lungs to develop, neonatal doctors give them oxygen and drugs to help them breathe.
These treatments contribute to a chronic lung disease known as Bronchopulmonary dysplasia (BPD). At present there is no treatment to heal the lungs of these premature babies.
50% of babies born before 28 weeks will get chronic lung disease. Case studies have shown that as these babies grow up, they continue to struggle with lung disease, coping with reduced lung function and early aging of their lungs.
Karen Thomas | EurekAlert!
Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin
Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care
Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.
Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....
Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.
The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....
An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.
We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...
Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.
Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...
An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...
24.05.2017 | Event News
23.05.2017 | Event News
22.05.2017 | Event News
26.05.2017 | Life Sciences
26.05.2017 | Life Sciences
26.05.2017 | Physics and Astronomy